Literature DB >> 7912911

Anesthetic and hemodynamic interactions of dexmedetomidine and fentanyl in dogs.

M T Salmenperä1, F Szlam, C C Hug.   

Abstract

BACKGROUND: Anesthetic doses of dexmedetomidine (DMED), a highly selective alpha 2 agonist, are not well tolerated hemodynamically. The combination of an opioid with DMED might reduce the dosage requirements for each drug and thereby allow the same anesthetic depth to be achieved with lesser degrees of their individual side effects.
METHODS: Dogs were anesthetized with enflurane. One group (n = 5) received intravenous doses of DMED from 0.1 to 10 micrograms/kg. Two other groups of five dogs each received fentanyl 15 micrograms/kg plus 0.05 microgram.kg-1.min-1 or fentanyl 45 micrograms/kg plus 0.2 micrograms.kg-1.min-1. Thereafter, they received DMED doses of 0.03-3 micrograms/kg. After the effects of the last DMED dose were measured, atipamezole 0.3 mg/kg was infused intravenously and all measurements were repeated. Then, naloxone (1 mg/kg) was injected intravenously and a final set of measurements obtained. Anesthetic effects were assessed by determining enflurane minimum alveolar concentration (MAC). Hemodynamics and plasma fentanyl concentrations were measured at each determination of MAC.
RESULTS: DMED and fentanyl individually produced dose-related reductions of enflurane MAC. During the lower rate infusion of fentanyl (plasma fentanyl concentration 1.0 +/- 0.3 ng/ml), DMED reduced enflurane MAC more than could be attributed to a simple additive interaction. During the higher rate infusion of fentanyl (plasma fentanyl concentration 4.4 +/- 0.7 ng/ml), DMED reduced enflurane MAC to greater degrees than were achievable by fentanyl alone. DMED caused a dose-dependent increase in arterial pressure concomitantly with a decrease in cardiac output, and these changes were not modified by fentanyl. The bradycardia following DMED was augmented by fentanyl.
CONCLUSIONS: There was a positive interaction, additive or synergistic, between DMED and fentanyl with respect to their enflurane-sparing effects. The interaction allowed the same depth of anesthesia to be achieved by lower doses of all three drugs, potentially limiting the intensity of their individual side effects. However, the presence of fentanyl increased the degree of bradycardia induced by DMED.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7912911     DOI: 10.1097/00000542-199404000-00017

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  6 in total

Review 1.  Dexmedetomidine: antiarrhythmic effects in the pediatric cardiac patient.

Authors:  Joseph D Tobias; Constantinos Chrysostomou
Journal:  Pediatr Cardiol       Date:  2013-02-24       Impact factor: 1.655

Review 2.  Dexmedetomidine: applications for the pediatric patient with congenital heart disease.

Authors:  Joseph D Tobias; Punkaj Gupta; Aymen Naguib; Andrew R Yates
Journal:  Pediatr Cardiol       Date:  2011-09-10       Impact factor: 1.655

3.  The effects of DEX premedication on volatile induction of mask anesthesia (VIMA) and sevoflurane requirements.

Authors:  Ayse Mizrak; Suleyman Ganidagli; Mehri T Cengiz; Unsal Oner; Vahap Saricicek
Journal:  J Clin Monit Comput       Date:  2013-02-12       Impact factor: 2.502

4.  Anesthetic management of deep brain stimulator implantation in Meige's syndrome.

Authors:  Kalpesh V Bhoyar; Pinakin Gujjar; Shashikant Shinde; Nirav Kotak
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2012-01

5.  Significant Bradycardia in Critically Ill Patients Receiving Dexmedetomidine and Fentanyl.

Authors:  Channing Hui; Maria Cardinale; Balaji Yegneswaran
Journal:  Case Rep Crit Care       Date:  2017-09-06

6.  Cardiovascular and renal effects of constant rate infusions of remifentanil, dexmedetomidine and their combination in dogs anesthetized with sevoflurane.

Authors:  Natsuki Akashi; Yusuke Murahata; Masahumi Hosokawa; Yoshiaki Hikasa; Yoshiharu Okamoto; Tomohiro Imagawa
Journal:  J Vet Med Sci       Date:  2020-12-11       Impact factor: 1.267

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.